Our results are consistent with another clustering work28 in an independent cohort of 151 patients with AD, in which a group with higher levels of Tau and lower amyloid levels was associated with worse clinical outcomes over time, including faster cognitive decline and higher mortality. This evidence concerns the gene MAPT and Mental deterioration.